Valeria Visconte Lab | Lerner Research Institute

Principal Investigator

Valeria Visconte, PhD

Project Staff
Email: [email protected]
Location: Cleveland Clinic Main Campus

Research

My research focuses on the study of a blood disorder called myelodysplastic syndrome. In this disease bone marrow cells, called stem cells stop producing blood cells, acquire genetic defects and can initiate more aggressive diseases. There are very few drugs to treat myelodysplastic syndrome and there is an urgent need to find new effective therapies. In the latest years many specific defects to DNA, called mutations, were discovered in this disease. Such mutations affect genes which carry information for important functions of the body, in the case of myelodysplastic syndrome, the bone marrow is not able to produce blood cells properly. I am a PhD scientist and the major goal of my research is to understand the genetic basis of myelodysplastic syndrome in order to develop new cures for patients with these disorders. New therapies are needed to give patients more options for treatment. My current research focuses to integrate many genetic aspects of the disease to better identify precise targets for treatment.

Biography

Valeria Visconte, PhD, is Project Staff in the Department of Translational Hematology & Oncology Research, Taussig Cancer Institute, Cleveland Clinic. Dr. Visconte's research focuses on the elucidation of genetic mechanisms driving the pathogenesis of bone marrow failure disorders, specifically myelodysplastic syndrome and integrates genetics with experimental therapeutics. Her research has been extensively involved in the investigation of the functional consequences of somatic mutations in a gene called splicing factor 3b subunit 1 (SF3B1) in myelodysplastic syndromes and has spanned several aspects of disorders related to myelodysplastic syndrome. Dr. Visconte is also an assistant Professor of Medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University and a problem based learning educator at the same institution.

Dr. Visconte received awards specific for her line of research. She received the American Society of Hematology Scholar Award (Basic/translational research), the Aplastic Anemia and MDS International Foundation Research Grant and the Vera & Joseph Dresner Foundation for MDS research. She is currently a recipient of a multi-PI R21 aiming to target defective spliceosomal pathways in myeloid malignancies, a Fast Track & Multi-Omics Funding from Lerner Research Institute and a VeloSano 9 Pilot Award.

Dr. Visconte completed a bachelor in Biology with summa cum laude at the Faculty of Mathematics, Physics and Natural Sciences, “Federico II” University of Naples, Naples, Italy. After that she pursued a PhD in Molecular Genetics at the same institution. She completed two fellowship trainings: one at the NHLBI, NIH and one at Cleveland Clinic to pursue genomic studies of bone marrow failures, specifically myelodysplastic syndromes. Her scientific contributions in bone marrow failure disorders have led to 112 peer-reviewed articles and three book chapters.

Dr. Visconte is a scientific reviewer of a number of hematology journals and funding agencies. Her work was featured in article cover pages, plenary paper, commentary and podcasts in Blood journal and other hematology journals. She is an academic editor of Cancers journal. She is a former member of the American Society of Hematology, Scientific Committee, Iron and Heme and has served as conference moderator at several American Society of Hematology meetings.

Education & Professional Highlights

Appointed

2010

Education & Fellowship

Fellowship- National Heart, Lung and Blood Institute, NIH, Bethesda, MD

Pre-Doctoral Visiting Fellow

2006-2007

Post-Doctoral Visiting Fellow

2007-2010

Fellowship-Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

Post-Doctoral Research Fellow

2010-2014

Faculty appointment

Research associate, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

2014-2015

Project Staff, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

2015-present

Assistant professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University

2017-present

Problem based learning eductator

2022-present

Certification

Board-certified in Biology, “Federico II’’ University of Naples, Italy.

Awards & Honors

American Society of Hematology, Scientific Committee, Iron and Heme

American Society of Hematology Scholar Award

Abstract Achievement Award, American Society of Hematology

Active Memberships

American Society of Hematology

International PNH Interest Group (IPIG)

Research

Research Interests:

Application of machine learning alghoritms to integrate genomic and transcriptomic data in myeloid malignancies.
New application schemes for gene mutations myeloid neoplasms and identification of molecular patterns in myeloid malignancies.
Genetic of splicing factor gene mutations. Discovery of novel drugs targeting cells with myelodysplastic syndromes and splicing factor mutations.
Involvement of RNA helicases variants in myeloid malignancies.
Understanding the genetic of VEXAS.

Our Team

Publications

Selected Publications

View publications for Valeria Visconte, PhD
(Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)

Durmaz A, Gurnari C, Hershberger CE, Pagliuca S, Daniels N, Awada H, Awada H, Adema V, Mori M, Ponvilawan B, Kubota Y, Kewan T, Bahaj WS, Barnard J, Scott J, Padgett RA, Haferlach T, Maciejewski JP, Visconte V. A multimodal analysis of genomic and RNA splicing features in myeloid malignancies. iScience. 2023 Feb 18;26(3):106238. 36926651

Awada H, Visconte V. The Heterogeneous Complexity of Myeloid Neoplasm: Multi-level Approaches to Study the Disease. Editorial. Cancers (Basel). 2023 Feb 24;15(5):1449. doi: 10.3390/cancers15051449. 36900241

Gurnari Carmelo, Visconte Valeria. From bone marrow failure syndromes to VEXAS: Disentangling clonal hematopoiesis, immune system, and molecular drivers. Leuk Res. 2023. 36841022

Kewan Tariq, Bahaj Waled, Durmaz Arda, Aly Mai Mostafa, Ogbue Olisaemeka D, Carraway Hetty E, Visconte Valeria, Gurnari Carmelo, Maciejewski Jaroslaw P. Validation of the Molecular International Prognostic Scoring System in patients with myelodysplastic syndromes. Blood. 2023. 36720101.

Pagliuca Simona, Gurnari Carmelo, Zhang Keman, Kewan Tariq, Bahaj Waled, Mori Minako, Nautiyal Ishani, Maciejewski Jaroslaw P, Wang Li, Visconte Valeria. Comprehensive Transcriptomic Analysis of VISTA in Acute Myeloid Leukemia: Insights into Its Prognostic Value. Int J Mol Sci. 2022. 36499220.

Kubota Yasuo, Zawit Misam, Durrani Jibran, Shen Wenyi, Bahaj Waled, Kewan Tariq, Ponvilawan Ben, Mori Minako, Gurnari Carmelo, LaFramboise Thomas, Visconte Valeria, Maciejewski Jaroslaw P. Significance of hereditary gene alterations for the pathogenesis of adult bone marrow failure versus myeloid neoplasia. Leukemia. 2022. 36266327.

Pagliuca Simona, Gurnari Carmelo, Terkawi Laila, Mori Minako, Visconte Valeria, Maciejewski Jaroslaw P. Molecular landscape of immune pressure and escape in aplastic anemia. Leukemia. 2023. 36253429.

Gurnari Carmelo, Mannion Peter, Pandit Ishani, Pagliuca Simona, Maciejewski Jaroslaw P, Visconte Valeria, Rogers Heesun J. Screening in Sweet Syndrome With Hematological Neoplasms Reveals a Novel Association Between VEXAS and Chronic Myelomonocytic Leukemia. Hemasphere. 2022. 36187875.

Pagliuca Simona, Gurnari Carmelo, Visconte Valeria. Individual HLA heterogeneity and its implications for cellular immune evasion in cancer and beyond. Front Immunol. 2022. 36131910.

Gurnari Carmelo, Pagliuca Simona, Patel Bhumika J, Durmaz Arda, Visconte Valeria, Maciejewski Jaroslaw P. Clinical and Molecular Determinants of Clonal Evolution in Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria. J Clin Oncol. 2023. 36054881.

Maciejewski Jaroslaw P, Visconte Valeria. Targeting the EIF2AK1 Signaling Pathway Rescues Red Blood Cell Production in SF3B1-Mutant Myelodysplastic Syndromes With Ringed Sideroblasts. Blood Cancer Discov. 2022. 35926182.

Hong Sanghee, Rybicki Lisa, Gurnari Carmelo, Pagliuca Simona, Zhang Aiwen, Thomas Dawn, Visconte Valeria, Sobecks Ronald M, Kalaycio Matt, Gerds Aaron T, Carraway Hetty E, Mukherjee Sudipto, Advani Anjali S, Patel Bhumika J, Maciejewski Jaroslaw P. Pattern of somatic mutation changes after allogeneic hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes. Bone Marrow Transplant. 2022. 35896698.

Kongkiatkamon Sunisa, Terkawi Laila, Guan Yihong, Adema Vera, Hasipek Metis, Dombrovski Tatiana, Co Milo, Awada Hassan, Parker Yvonne, Pagliuca Simona, Gurnari Carmelo, Rogers Heesun J, Lindner Daniel J, Visconte Valeria, LaFramboise Thomas, Jha Babal K, Maciejewski Jaroslaw P. Rare germline alterations of myeloperoxidase predispose to myeloid neoplasms. Leukemia. 2022. 35761024.

Adema Vera, La Framboise Thomas, Radivoyevitch Tomas, Visconte Valeria, Sekeres Mikkael, Barnard John, Maciejewski Jaroslaw P. Pathophysiologic and clinical implications of molecular profiles resultant from deletion 5q. EBioMedicine. 2022. 35617825.

Visconte Valeria, Maciejewski Jaroslaw P. Clonal dynamics of hematopoietic stem cell compartment in aplastic anemia. Semin Hematol. 2022. 35491059.

Awada Hussein, Gurnari Carmelo, Durmaz Arda, Pagliuca Simona, Visconte Valeria. Personalized Risk Schemes and Machine Learning to Empower Genomic Prognostication Models in Myelodysplastic Syndromes. Int J Mol Sci. 2022. 35269943.

Gurnari Carmelo, Pagliuca Simona, Durmaz Arda, Zawit Misam, Maciejewski Jaroslaw P, Visconte Valeria. A study of Telomerase Reverse Transcriptase rare variants in myeloid neoplasia. Hematol Oncol. 2022. 35106810.

Gurnari Carmelo, Pagliuca Simona, Visconte Valeria. Alternative Splicing in Myeloid Malignancies. Biomedicines. 2021. 34944660.

Kongkiatkamon Sunisa, Pagliuca Simona, Adema Vera, Nagata Yasunobu, Kerr Cassandra M, Awada Hassan, Gurnari Carmelo, Rogers Heesun J, Saunthararajah Yogen, Visconte Valeria, Maciejewski Jaroslaw P. Molecular characterization of the histone acetyltransferase CREBBP/EP300 genes in myeloid neoplasia. Leukemia. 2022. 34845315.

Gurnari Carmelo, Pagliuca Simona, Kewan Tariq, Bahaj Waled, Mori Minako, Patel Bhumika J, Visconte Valeria, Maciejewski Jaroslaw P. Is nature truly healing itself? Spontaneous remissions in Paroxysmal Nocturnal Hemoglobinuria. Blood Cancer J. 2021. 34839350.

Gurnari Carmelo, Pagliuca Simona, Guan Yihong, Hershberger Courtney E, Ni Ying, Awada Hassan, Kongkiatkamon Sunisa, Zawit Misam, Jha Babal K, Maciejewski Jaroslaw P, Visconte Valeria. TET2 mutations as a part of DNA dioxygenase deficiency in myelodysplastic syndromes. Blood Adv. 2022. 34768283.

Pagliuca Simona, Gurnari Carmelo, Awada Hassan, Kishtagari Ashwin, Kongkiatkamon Sunisa, Terkawi Laila, Zawit Misam, Guan Yihong, LaFramboise Thomas, Jha Babal K, Patel Bhumika J, Hamilton Betty K, Majhail Navneet S, Saunthararajah Yogen, Visconte Valeria, Chan Timothy A, Maciejewski Jaroslaw P. The similarity of class II HLA genotypes defines patterns of autoreactivity in idiopathic bone marrow failure disorders. Blood. 2021. 34748628.

Gurnari Carmelo, Visconte Valeria. 'We cannot paint them all with the same brush': the need for a better definition of patients with myelodysplastic syndromes for clinical trial design. Br J Haematol. 2022. 34693518.

Dermawan Josephine K, Wensel Christine, Visconte Valeria, Maciejewski Jaroslaw P, Cook James R, Bosler David S. Clinically Significant CUX1 Mutations Are Frequently Subclonal and Common in Myeloid Disorders With a High Number of Co-mutated Genes and Dysplastic Features. Am J Clin Pathol. 2022. 34661647.

Gurnari Carmelo, Pagliuca Simona, Awada Hassan, Zawit Misam, Patel Bhumika J, Visconte Valeria, Valent Jason, Rogers Heesun J, Maciejewski Jaroslaw P. Monoclonal IgM gammopathy in adult acquired pure red cell aplasia: culprit or innocent bystander? Blood Cells Mol Dis. 2021. 34280665.

Pagliuca Simona, Gurnari Carmelo, Zhao Ran, Kongkiatkamon Sunisa, Terkawi Laila, Zawit Misam, Guan Yihong, Awada Hassan, Kishtagari Ashwin, Kerr Cassandra M, LaFramboise Thomas, Patel Bhumika J, Jha Babal K, Visconte Valeria, Maciejewski Jaroslaw P. Clinical and basic implications of dynamic T cell receptor clonotyping in hematopoietic cell transplantation. JCI Insight. 2021. 34236054.

Awada Hassan, Durmaz Arda, Gurnari Carmelo, Kishtagari Ashwin, Kerr Cassandra M, Kuzmanovic Teodora, Durrani Jibran, Shreve Jacob, Nagata Yasunobu, Radivoyevitch Tomas, Advani Anjali S, Carraway Hetty E, Nazha Aziz, Saunthararajah Yogen, Scott Jacob, Visconte Valeria, Sekeres Mikkael A, Maciejewski Jaroslaw P. Machine learning integrates genomic signatures for subclassification beyond primary and secondary acute myeloid leukemia. Blood. 2021. 34075412.

Gurnari Carmelo, Pagliuca Simona, Visconte Valeria. The Interactome between Metabolism and Gene Mutations in Myeloid Malignancies. Int J Mol Sci. 2021. 33808599.

Gurnari Carmelo, Pagliuca Simona, Durkin Lisa, Terkawi Laila, Awada Hassan, Kongkiatkamon Sunisa, Zawit Misam, Hsi Eric D, Carraway Hetty E, Rogers Heesun J, Visconte Valeria, Maciejewski Jaroslaw P. Vacuolization of hematopoietic precursors: an enigma with multiple etiologies. Blood. 2021. 33690844.

Pagliuca Simona, Gurnari Carmelo, Visconte Valeria. Molecular Targeted Therapy in Myelodysplastic Syndromes: New Options for Tailored Treatments. Cancers (Basel). 2021. 33668555.

Awada Hassan, Durmaz Arda, Gurnari Carmelo, Kishtagari Ashwin, Zawit Misam, Pagliuca Simona, Visconte Valeria. Friend or foe? The case of Wilms' Tumor 1 (WT1) mutations in acute myeloid leukemia. Blood Cells Mol Dis. 2021. 33636567.

Awada Hassan, Kerr Cassandra M, Durmaz Arda, Adema Vera, Gurnari Carmelo, Pagliuca Simona, Zawit Misam, Kongkiatkamon Sunisa, Rogers Heesun J, Saunthararajah Yogen, Sekeres Mikkael A, Carraway Hetty, Maciejewski Jaroslaw P, Visconte Valeria. Clonal trajectories and cellular dynamics of myeloid neoplasms with SF3B1 mutations. Leukemia. 2021. 33603144.

Gurnari Carmelo, Pagliuca Simona, Patel Bhumika J, Awada Hassan, Kongkiatkamon Sunisa, Terkawi Laila, Zawit Misam, Corey Seth, Lichtin Alan E, Carraway Hetty E, Visconte Valeria, Maciejewski Jaroslaw P. Implication of PIGA genotype on erythrocytes phenotype in Paroxysmal Nocturnal Hemoglobinuria. Leukemia. 2021. 33483614.

Gurnari Carmelo, Durrani Jibran, Pagliuca Simona, Kishtagari Ashwin, Awada Hassan, Kerr Cassandra M, Adema Vera, Kongkiatkamon Sunisa, Lichtin Alan E, Patel Bhumika J, Visconte Valeria, Sekeres Mikkael A, Cook James R, Maciejewski Jaroslaw P. Novel invariant features of Good syndrome. Leukemia. 2021. 33414481.

Gurnari Carmelo, Graham Amy C, Efanov Alexey, Pagliuca Simona, Durrani Jibran, Awada Hassan, Patel Bhumika J, Lichtin Alan E, Visconte Valeria, Sekeres Mikkael A, Maciejewski Jaroslaw P. Frequency and perturbations of various peripheral blood cell populations before and after eculizumab treatment in paroxysmal nocturnal hemoglobinuria. Blood Cells Mol Dis. 2021. 33341510.

Awada Hassan, Visconte Valeria. The Genomics of Myelodysplastic Syndromes: Origins of Disease Evolution, Biological Pathways, and Prognostic Implications. Cells. 2020. 33233642.

Gurnari Carmelo, Pagliuca Simona, Visconte Valeria. Deciphering the Therapeutic Resistance in Acute Myeloid Leukemia. Int J Mol Sci. 2020. 33198085.

Adema Vera, Khouri Jack, Ni Ying, Rogers Heesun J, Kerr Cassandra M, Awada Hassan, Nagata Yasunobu, Kuzmanovic Teodora, Advani Anjali S, Gerds Aaron T, Mukherjee Sudipto, Nazha Aziz, Saunthararajah Yogen, Madanat Yazan, Patel Bhumika J, Sekeres Mikkael A, Maciejewski Jaroslaw P, Visconte Valeria, Carraway Hetty E. Analysis of distinct hotspot mutations in relation to clinical phenotypes and response to therapy in myeloid neoplasia. Leuk Lymphoma. 2021. 33140678.

Guan Yihong, Greenberg Edward F, Hasipek Metis, Kerr Cassandra M, Radivoyevitch Tomas, Gu Xiaorong, Willard Belinda, Visconte Valeria, Makishima Hideki, Nazha Aziz, Sekeres Mikkael A, Saunthararajah Yogen, Maciejewski Jaroslaw P, Jha Babal K. Context dependent effects of ascorbic acid treatment in TET2 mutant myeloid neoplasia. Commun Biol. 2020. 32895473.

Hershberger Courtney. HHEX promotes myeloid transformation in cooperation with mutant ASXL1. Blood. 2020. 32492700.

Gurnari Carmelo, Maciejewski Jaroslaw P, Visconte Valeria. From Bench to Bedside and Beyond: Therapeutic Scenario in Acute Myeloid Leukemia. Cancers (Basel). 2020. 32033196.

Awada Hassan, Mahfouz Reda Z, Durrani Jibran, Kishtagari Ashwin, Jagadeesh Deepa, Lichtin Alan E, Hill Brian T, Hamilton Betty K, Carraway Hetty E, Nazha Aziz, Majhail Navneet S, Sobecks Ronald, Visconte Valeria, Kalaycio Matt, Sekeres Mikkael A, Maciejewski Jaroslaw P. Large granular lymphocytic leukaemia after solid organ and haematopoietic stem cell transplantation. Br J Haematol. 2020. 31958160.

Visconte Valeria, O Nakashima Megan, J Rogers Heesun. Mutations in Splicing Factor Genes in Myeloid Malignancies: Significance and Impact on Clinical Features. Cancers (Basel). 2019. 31766606.

Awada Hassan, Mahfouz Reda Z, Kishtagari Ashwin, Kuzmanovic Teodora, Durrani Jibran, Kerr Cassandra M, Patel Bhumika J, Visconte Valeria, Radivoyevitch Tomas, Lichtin Alan, Carraway Hetty E, Maciejewski Jaroslaw P, Saunthararajah Yogen. Extended experience with a non-cytotoxic DNMT1-targeting regimen of decitabine to treat myeloid malignancies. Br J Haematol. 2020. 31736067.

Durrani Jibran, Awada Hassan, Kishtagari Ashwin, Visconte Valeria, Kerr Cassandra, Adema Vera, Nagata Yasunobu, Kuzmanovic Teodora, Hong Sanghee, Patel Bhumika, Nazha Aziz, Lichtin Alan, Mukherjee Sudipto, Saunthararajah Yogen, Carraway Hetty, Sekeres Mikkael, Maciejewski Jaroslaw P. Large granular lymphocytic leukemia coexists with myeloid clones and myelodysplastic syndrome. Leukemia. 2020. 31624375.

Awada Hassan, Rahman Shafia, Durrani Jibran, Asad Mohammad F, Kerr Cassandra M, Adema Vera, Kishtagari Ashwin, Graham Amy, Snider Christina A, Kongkiatkamon Sunisa, Nagata Yasunobu, Patel Bhumika J, Carraway Hetty E, Sekeres Mikkael A, Maciejewski Jaroslaw P, Visconte Valeria. Leukemia evolving from paroxysmal nocturnal hemoglobinuria. Leukemia. 2020. 31431736.

Han Yingchun, Visconte Valeria, Przychodzen Bartlomiej, Phillips James, Advani Anjali, Carraway Hetty E, Sekeres Mikkael A, Maciejewski Jaroslaw P. The novel autophagy inhibitor ROC-325 augments the antileukemic activity of azacitidine. Leukemia. 2019. 31358855.

Aly Mai, Nagata Yasunobu, Balasubramanian Suresh K, Visconte Valeria, Kuzmanovic Teodora, Adema Vera, Przychodzen Bartlomiej P, Kerr Cassandra M, Abazeed Mohamed E, Maciejewski Jaroslaw P. Distinct clinical and biological implications of in myeloid neoplasms. Blood Adv. 2019. 31320321.

Visconte Valeria. Rational cotargeting of HDAC6 and BET proteins yields synergistic antimyeloma activity. Blood Adv. 2019. 31015208.

Advani Anjali S, Cooper Brenda, Visconte Valeria, Elson Paul, Chan Ricky, Wei Wei, Mukherjee Sudipto, Gerds Aaron, Carraway Hetty, Nazha Aziz, Hamilton Betty, Sobecks Ronald, Caimi Paolo, Tomlinson Benjamin, Malek Ehsan, Little Jane, Miron Alexander, Pink John, Maciejewski Jaroslaw, Unger Allison, Kalaycio Matt, de Lima Marcos, Sekeres Mikkael A. A Phase I/II Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid Leukemia. Clin Cancer Res. 2019. 30992301.

Lichtin Alan E, Radivoyevitch Tomas, Sekeres Mikkael A. Subclonal STAT3 mutations solidify clonal dominance. Blood Adv. 2019. 30898763.

Radivoyevitch Tomas. Invariant phenotype and molecular association of biallelic mutant myeloid neoplasia. Blood Adv. 2019. 30709865.

Xie Yan, Visconte Valeria, Rogers Heesun J. The first concurrent diagnosis of acute symptomatic Babesiosis and chronic myeloid leukemia in a healthy young adult. Blood Res. 2018. 29963524.

1. Kewan T, Bahaj WS, Durmaz A, Aly M, Ogbue OD, Carraway HE, Sekeres MA, Visconte V, Gurnari C, Maciejewski JP. Validation of the Molecular International Prognostic Scoring System in patients with myelodysplastic syndromes. Blood. 2023. Jan 30:blood.2022018896. doi: 10.1182/blood.2022018896.2023.

2. Pagliuca S, Gurnari C, Zhang K, Kewan T, Bahaj W, Mori M, Nautiyal I, Rubio MT, Ferraro F, Maciejewski JP, Wang L, Visconte V. Comprehensive Transcriptomic Analysis of VISTA in Acute Myeloid Leukemia: Insights into Its Prognostic Value. Int J Mol Sci. 2022 Nov 28;23(23):14885. doi: 10.3390/ijms232314885.

3. Kubota Y, Zawit M, Durrani J, Shen W, Bahaj W, Kewan T, Ponvilawan B, Mori M, Meggendorfer M, Gurnari C, LaFramboise T, Feurstein S, Sekeres MA, Visconte V, Godley LA, Haferlach T, Maciejewski JP. Significance of hereditary gene alterations for the pathogenesis of adult bone marrow failure versus myeloid neoplasia. Leukemia. 2022 Oct 20. doi: 10.1038/s41375-022-01729-4.

4. Pagliuca S, Gurnari C, Hercus C, Hergalant S, Nadarajah N, Wahida A, Terkawi L, Mori M, Zhou W, Visconte V, Spellman S, Gadalla S, Zhu C, Zhu P, Haferlach T, Maciejewski JP. Molecular landscape of immune pressure and escape in aplastic anemia. Leukemia. 2022 Oct 17. doi: 10.1038/s41375-022-01723-w.

5. Gurnari C, Mannion P, Pandit I, Pagliuca S, Voso MT, Maciejewski JP, Visconte V, Rogers HJ. UBA1 screening in Sweet syndrome with hematological neoplasms reveals a novel association between VEXAS and chronic myelomonocytic leukemia. HemaSphere. Sep 27;6(10):e775. doi: 10.1097/HS9.0000000000000775. eCollection 2022 Oct.

6. Pagliuca S, Gurnari C, Rubio MT, Visconte V, Lenz TL. Individual HLA heterogeneity and its implications for cellular immune evasion in cancer and beyond. Front Immunol. 2022. Sep 5;13:944872. doi: 10.3389/fimmu.2022.944872. eCollection 2022.

7. Gurnari C, Pagliuca S, Prata PH, Galimard JE, Catto LFB, Larcher L, Sebert M, Allain V, Patel BJ, Durmaz A, Pinto AL, Inacio MCB, Hernandez L, Dhedin N, Caillat-Zucman S, Clappier E, Sicre de Fontbrune F, Voso MT, Visconte V, Peffault de Latour R, Soulier J, Calado RT, Socié G, Maciejewski JP.Clinical and Molecular Determinants of Clonal Evolution in Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria. J Clin Oncol. 2022 Sep 2:JCO2200710. doi: 10.1200/JCO.22.00710. Online ahead of print.

8. Adema V, Ma F, Kanagal-Shamanna R, Thongon N, Montalban-Bravo G, Yang H, Peslak SA, Wang F, Acha P, Sole F, Lockyer P, Cassari M, Maciejewski JP, Visconte V, Ganan-Gomez I, Song Y, Bueso-Ramos C, Pellegrini M, Tan TM, Bejar R, Carew JS, Halene S, Santini V, Al-Atrash G, Clise-Dwyer K, Garcia-Manero G, Blobel GA, Colla S. Targeting the EIF2AK1 signaling pathway rescues red blood cell production in SF3B1-mutant myelodysplastic syndromes with ringed sideroblasts. Blood Cancer Discov. 2022 Aug 4:BCD-21-0220. doi: 10.1158/2643-3230.BCD-21-0220.

9. Hong S, Rybicki L, Gurnari C, Pagliuca S, Zhang A, Thomas D, Visconte V, Durrani J, Sobecks R, Kalaycio M, Gerds A, Carraway H, Mukherjee S, Sekeres M, Advani A, Majhail N, Hamilton BK, Patel B, Maciejewski JP. Pattern of Somatic Mutation Changes after Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. Bone Marrow Transplant. 2022 Jul 27. doi: 10.1038/s41409-022-01762-y.

10. Kongkiatkamon S, Terkawi L, Guan Y, Adema V, Hasipek M, Dombrovski T, Co M, Walter W, Awada H, Parker Y, Hutter S, Pagliuca S, Gurnari C, Rogers H, Meggendorfer M, Lindner D, Haferlach T, Visconte V, LaFramboise T, Jha BK, Maciejewski JP. Rare Germline Alterations of Myeloperoxidase Predispose to Myeloid Neoplasms. Leukemia. 2022 Jun 27. doi: 10.1038/s41375-022-01630-0.

11. Adema V, Palomo L, Walter W, Mallo M, Hutter S, La Framboise T, Arenillas L, Meggendorfer M, Radivoyevitch T, Xicoy B, Pellagatti A, Haferlach C, Boultwood J, Kern W, Visconte V, Sekeres M, Barnard J, Haferlach T, Solé F, Maciejewski JP. Pathophysiologic and clinical implications of molecular profiles resultant from deletion 5q. EBioMedicine. 2022 Jun; 80:104059. doi: 10.1016/j.ebiom.2022.104059. Epub 2022 May 23.

12. Visconte V, Maciejewski JP. Clonal dynamics of hematopoietic stem cell compartment in aplastic anemia. Semin Hematol. 2022 Jan;59(1):47-53. doi: 10.1053/j.seminhematol.2021.12.003.

13. Awada H, Gurnari C, Durmaz A, Awada H, Pagliuca S, Visconte V. Personalized risk schemes and machine learning to empower genomic prognostication models in myelodysplastic syndromes. Int J Mol Sci. 2022 Mar 3;23(5):2802. doi: 10.3390/ijms23052802

14. Gurnari C, Wahida A, Pagliuca S, Durmaz A, Zawit M, Haferlach T, Maciejewski JP, Visconte V. A study of TERT rare variants in myeloid neoplasia. Hematol Oncol. 2022 Feb 1. doi: 10.1002/hon.2967.

15. Gurnari C, Pagliuca S, Visconte V. Alternative Splicing in Myeloid Malignancies. Biomedicines. 2021 Dec 6;9(12):1844. doi: 10.3390/biomedicines9121844.

16. Kongkiatkamon S, Pagliuca, S, Adema A, Nagata Y, Kerr C, Walter W, Awada H, Hutter S, Gurnari C, Rogers HJ, Meggendorfer M, Saunthararajah Y, Haferlach T, Visconte V, Maciejewski JP. Molecular Characterization of the Histone Acetyltransferase CREBBP/EP300 Genes in Myeloid Neoplasia. Leukemia. 2021 Nov 29. doi: 10.1038/s41375-021-01479-9.

17. Gurnari C, Pagliuca S, Kewan T, Bahaj W, Mori M, Patel BJ, Visconte V, and Jaroslaw Maciejewski. Is nature truly healing itself? Spontaneous remissions in Paroxysmal Nocturnal Hemoglobinuria. Blood Cancer J. 2021. Nov 27;11(11):187. doi: 10.1038/s41408-021-00582-5.

18. Gurnari C, Pagliuca S, Guan Y, Adema V, Hershberger CE, Ni Y, Awada H, Kongkiatkamon S, Zawit M, Coutinho DF, Zalcberg IR, Ahn J-S, Kim H-J, Kim DDH, Minden MD, Jansen JH, Meggendorfer M, Haferlach C, Jha BK, Haferlach T, Maciejewski JP, Visconte V. TET2 mutations as a part of DNA dioxygenase deficiency in myelodysplastic syndromes. Blood Adv. 2021. Nov 12:bloodadvances.2021005418. doi: 10.1182/bloodadvances.2021005418.

19. Pagliuca S, Gurnari C, Awada H, Kishtagari A, Kongkiatkamon S, Terkawi L, Zawit M, Guan Y, LaFramboise T, Jha BK, Patel BJ, Hamilton B, Majhail NS, Lundgren S, Mustjoki S, Saunthararajah Y, Visconte V, Chan T, Yang C-Y, Lenz TL, Maciejewski JP.The similarity of Class II HLA Genotypes Defines Patterns of Autoreactivity in Idiopathic Bone Marrow Failure Disorders. Blood. 2021. Nov 5:blood.2021012900. doi: 10.1182/blood.2021012900.

20. Gurnari C, Visconte V. We cannot paint them all with the same brush’: the need for a better definition of patients with myelodysplastic syndromes for clinical trial design. Commentary. Br J Haematol. 2021 Oct 24. doi: 10.1111/bjh.17909.

21. Gurnari C, Pagliuca S, Awada H, Zawit M, Patel BJ, Visconte V, Valent J, Rogers HJ, Maciejewski JP. Monoclonal IgM gammopathy in adult acquired pure red cell aplasia: culprit or innocent bystander? Blood Cells Mol Dis. 2021 Nov; 91:102595. doi: 10.1016/j.bcmd.2021.102595. Epub 2021 Jul 14.

22. Awada H, Kerr CM, Durmaz A, Adema V, Gurnari C, Pagliuca S, Zawit M, Kongkiatkamon S, Rogers H, Saunthararajah Y, Sekeres MA, Carraway H, Maciejewski JP, Visconte V. Clonal Trajectories and Cellular Dynamics of Myeloid Neoplasms with SF3B1 Mutations. Leukemia. 2021 Feb 18. doi: 10.1038/s41375-021-01176-7.

23. Dermawan JK, Wensel C, Visconte V, Maciejewski JP, Cook JR, Bosler DS. Clinically Significant CUX1 Mutations Are Frequently Subclonal and Common in Myeloid Disorders With a High Number of Co-mutated Genes and Dysplastic Features. Am J Clin Pathol. 2021 Oct 18; aqab157. doi: 10.1093/ajcp/aqab157.

24. Pagliuca S, Gurnari C, Hong S, Zhao R, Kongkiatkamon S, Terkawi L, Zawit M, Guan Y, Awada H, Kishtagari A, Kerr CM, LaFramboise T, Patel BJ, Jha BK, Carraway HE, Visconte V, Majhail NS, Hamilton BK, Maciejewski JP. Clinical and basic implications of dynamic T cell receptor clonotyping in hematopoietic cell transplantation. JCI Insight. 2021 Jul 8;6(13):149080. doi: 10.1172/jci.insight.149080.

25. Awada H, Durmaz A, Gurnar C, Kishtagari A, Meggendorfer M, Kerr CM, Kuzmanovic T, Durrani J, Shreve J, Nagata Y, Radivoyevitch T, Advani AS, Ravandi F, Carrawa HE, Nazha A, Haferlach C, Saunthararajah Y, Scott J, Visconte V, Kantarjian H, Kadia T, Sekeres MA, Haferlach T, Maciejewski JP. Machine Learning Integrates Genomic Signatures for Subclassification Beyond Primary and Secondary Acute Myeloid Leukemia. Blood. Jun 1:blood.2020010603. doi: 10.1182/blood.2020010603.

26. Gurnari C, Pagliuca S, Visconte V. The interactome between metabolism and gene mutations in myeloid malignancies. Int J Mol Sci. 2021 Mar 19;22(6):3135. doi: 10.3390/ijms22063135. Review was added to Encyclopedia (https://encyclopedia.pub/9116)

27. Gurnari C, Pagliuca S, Durkin L, Terkawi L, Awada H, Kongkiatkamon S, Zawit M, Hsi ED, Carraway HE, Rogers HJ, Visconte V, Maciejewski JP. Vacuolization of hematopoietic precursors: an enigma with multiple etiologies. Blood. 2021 Mar 9:blood.2021010811. doi: 10.1182/blood.2021010811

28. Pagliuca S, Gurnari C, Visconte V. Molecular targeted therapy in myelodysplastic syndromes: new options for tailored treatments. Cancers (Basel). 2021 Feb; 13(4): 784. Cancers (Basel). 2021 Feb 13;13(4):784. doi: 10.3390/cancers13040784.

29. Awada, Durmaz A, Gurnari C, Kishtagari A, Zawit M, Pagliuca S, Visconte V. Friend or foe? The case of Wilms' Tumor 1 (WT1) mutations in acute myeloid leukemia. Blood Cells Mol Dis. 2021 May; 88:102549. doi: 10.1016/j.bcmd.2021.102549. Epub 2021 Feb 20.

30. Gurnari C, Pagliuca S, Patel BJ, Awada H, Kongkiatkamon S, Terkawi L, Zawit M, Corey S, Lichtin AE, Carraway HE, Wahida A, Visconte V, Maciejewski JP. Implication of PIGA genotype on erythrocytes phenotype in Paroxysmal Nocturnal Hemoglobinuria. Leukemia. 2021 Jan 22. doi: 10.1038/s41375-020-01113-0.

31. Gurnari C, Durrani J, Pagliuca S, Kishtagari A, Awada H, Kerr CM, Adema V, Kongkiatkamon S, Lichtin A, Patel BJ, Visconte V, Sekeres MA, Cook J. Maciejewski JP. Novel invariant features of Good syndrome. Leukemia. 2021 Jan 7. doi: 10.1038/s41375-020-01114-z.

32. Gurnari C, Graham AC, Efanov A, Pagliuca S, Durrani J, Awada H, Patel BJ, Lichtin AE, Visconte V, Sekeres MA, Maciejewski JP. Frequency and perturbations of various peripheral blood cell populations before and after eculizumab treatment in paroxysmal nocturnal hemoglobinuria.   Blood Cells Mol Dis. 2020 Dec 8; 87:102528. doi: 10.1016/j.bcmd.2020.102528.

33. Awada H, Thapa B, Visconte V. The Genomics of Myelodysplastic Syndromes: Origins of Disease Evolution, Biological Pathways, and Prognostic Implications. Cells. 2020 Nov 20;9(11):2512. doi: 10.3390/cells9112512.

34. Gurnari C, Pagliuca S, Visconte V. Deciphering the Therapeutic Resistance in Acute Myeloid Leukemia. Int J Mol Sci. 2020 Nov 12;21(22):8505. doi: 10.3390/ijms21228505.

35. Adema V, Khouri J, Ni Y, Rogers HJ, Kerr CM, Awada H, Nagata Y, Kuzmanovic T, Advani AS, Gerds AT, Mukherjee S, Nazha A, Saunthararajah Y, Madanat Y, Patel BJ, Solé F, Nawrocki ST, Carew JS, Sekeres MA, Maciejewski JP, Visconte V, Carraway HE. Analysis of Distinct SF3B1 Hotspot Mutations in Relation to Clinical Phenotypes and Response to Therapy in Myeloid Neoplasia. Leuk Lymphoma. 2020 Nov 3:1-4. doi: 10.1080/10428194.2020.1839647.

36. Guan Y, Greenberg EF, Hasipek M, Chen S, Liu X, Kerr CM, Gackowski D, Zarakowska E, Radivoyevitch T, Gu X, Willard B, Visconte V, Makishima H, Nazha A, Mukherji M, Sekeres MA, Saunthararajah Y, Oliński R, Xu M, Maciejewski JP, Jha BK. Context dependent effects of ascorbic acid treatment in TET2 mutant myeloid neoplasia. Commun Biol. 2020 Sep 7;3(1):493.

37. Takeda R, Asada S, Park S-J, Yokoyama A, Becker HJ , Kanai A, Visconte V, Hershberger C, Hayashi Y, Yonezawa T, Tamura M, Fukushima T, Tanaka Y, Fukuyama T, Matsumoto A, Yamasaki S, Nakai K, Yamazaki S, Inaba T, Shibata T, Inoue D , Honda H, Goyama S, Maciejewski JP, Kitamura T. HHEX promotes myeloid transformation in cooperation with mutant ASXL1. Blood. 2020 Jun 3; blood.2019004613.

38. Gurnari C, Voso MT, Maciejewski JP, Visconte V. From bench to bedside and beyond: therapeutic scenario in Acute Myeloid Leukemia. Cancers (Basel). 2020 Feb 4;12(2):357.

39. Awada H, Mahfouz RZ, Durrani J, Kishtagari A, Jagadeesh D, Lichtin AE, Hill BT, Hamilton BK, Carraway HE, Majhail NS, Sobecks R, Visconte V, Kalaycio M, Sekeres MA, Maciejewski JP. Large granular lymphocytic laeukemia after solid organ and haematopoietic stem cell transplantation. Br J Haematol. 2020 Apr;189(2):318-322. doi: 10.1111/bjh.16336.

40. Awada H, Rahman S, Durrani J, Asad MF, Kerr CM, Adema V, Kishtagari A, Graham A, Snider CA, Kongkiatkamon S, Nagata Y, Patel BJ, Carraway HE, Sekeres MA, Maciejewski JP, Visconte V. Leukemia evolving from paroxysmal nocturnal hemoglobinuria. Leukemia. 2020 Jan;34(1):327-330. doi: 10.1038/s41375-019-0555-0. Epub 2019 Aug 20.

41. Nawrocki S, Han Y, Visconte V, Przychodzen B, Espitia C, Phillips J, Anwer F, Advani A, Carraway H, Kelly K, Sekeres MA, Maciejewski JP, Carew JS. The novel autophagy inhibitor ROC-325 augments the anti-leukemic activity of azacitidine. Leukemia. 2019 Jul 29. doi: 10.1038/s41375-019-0529-2. [Epub ahead of print].

42. Visconte V, Nakashima MO, Rogers HJ. Mutations in Splicing Factor Genes in Myeloid Malignancies: Significance and Impact on Clinical Features. Cancers (Basel). 2019 Nov 22;11(12). pii: E1844.

43. Awada H, Mahfouz RZ, Kuzmanovic T, Durrani J, Kerr CM, Kishtagari A, Patel BJ, Visconte V, Radivoyevitch T, Lichtin A, Carraway HE, Maciejewski JP, Saunthararajah Y. Extended experience with a very low dose, metronomic, subcutaneous decitabine regimen to treat myelodysplastic syndromes. Br J Haematol. 2019 Nov 17. doi: 10.1111/bjh.16281.

44. Durrani J, Awada H, Kishtagari A, Visconte V, Kerr CM, Adema V, Nagata Y, Kuzmanovic T, Hong S, Patel BJ, Nazha A, Lichtin AE, Mukherjee S, Saunthararajah Y, Carraway HE, Sekeres MA, Maciejewski JP. Large granular lymphocytic leukemia coexists with myeloid clones and myelodysplastic syndrome. Leukemia. 2019 Oct 17. doi: 10.1038/s41375-019-0601-y.

45. Aly M, Ramdzan ZM, Nagata Y, Balasubramanian SK, Hosono N, Makishima H, Visconte V, Kuzmanovic T, Adema V, Nazha A, Przychodzen BP, Kerr CM, Sekeres MA, Abazeed ME, Nepveu A, Maciejewski JP. Distinct clinical and biological implications of CUX1 in myeloid neoplasms. Blood Adv. 2019 Jul 23;3(14):2164-2178.

46. Carew JS, Espitia CM, Zhao W, Visconte V, Anwer F, Kelly KR, Nawrocki ST. Rational co-targeting of HDAC6 and BET proteins yields synergistic anti-myeloma activity. Blood Adv. 2019 Apr 23;3(8):1318-1329.

47. Advani A, Cooper B, Visconte V, Elson P, Chan R, Carew JS, Wei W, Mukherjee S, Gerds A, Carraway H, Nazha A, Hamilton B, Sobecks R, Caimi P, Tomlinson B, Malek E, Little J, Miron A, Pink J, Maciejewski JP, Kalaycio M, De Lima M, Unger A, Sekeres MA. Phase 1/2 Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed/ Refractory Acute Myeloid Leukemia. Clin Cancer Res. Clin Cancer Res. 2019 Apr 16. pii: clincanres.3886.2018. doi: 10.1158/1078-0432.CCR-18-3886.

48. Kerr CM, Clemente MJ, Chomczynski P, Przychodzen B, Nagata Y, Adema V, Visconte V, Lichtin AE, Mustjoki S, Radivoyevitch T, Sekeres MA, Maciejewski JP. Subclonal STAT3 Mutations Solidify Clonal Dominance. Blood Adv. 2019 Mar 26;3(6):917-921.

49. Awada H, Nagata Y, Goyal A, Asad MF, Patel B, Hirsch CM, Kuzmanovic T, Guan Y, Przychodzen BP, Aly M, Adema V, Shen W, Williams L, Nazha A, Abazeed ME, Sekeres MA, Radivoyevitch T, Haferlach T, Jha BK, Visconte V, Maciejewski JP. Invariant phenotype and molecular association of biallelic TET2 mutant myeloid neoplasia. Blood Adv. 2019 Feb 12;3(3):339-349. doi: 10.1182/bloodadvances.2018024216.

50. Xie Y, Visconte V, Duan L, Rogers HJ. The first concurrent diagnosis of acute symptomatic Babesiosis and chronic myeloid leukemia in a healthy young adult. Blood Res. 2018 Jun;53(2):163-166. doi: 10.5045/br.2018.53.2.163. Epub 2018 Jun 25.

51. Hirsch C, Nazha A, Kneen K, Abazeed M, Meggendorfer M, Przychodzen B, Nadarajah N, Adema V, Nagata Y, Goyal A, Awada H, Asad M, Visconte V, Guan Y, Sekeres MA, Olinski R, Jha B, LaFramboise T, Radivoyevitch T, Haferlach T, Maciejewski JP. Consequences of Mutant TET2 Clonal and Subclonal Hierarchy. Leukemia. 2018 Aug;32(8):1751-1761. doi: 10.1038/s41375-018-0150-9. Epub 2018 May 24.

52. Palam LR, Mali RS, Ramdas B, Srivatsan SN, Visconte V, Tiu RV, Vanhaesebroeck B, Roers A, Gerbaulet A, Xu M, Janga SC, Takemoto CM, Paczesny S, Kapur R. Loss of epigenetic regulator TET2 and oncogenic KIT regulate myeloid cell transformation via PI3K pathway. JCI Insight. 2018 Feb 22;3(4). pii: 94679. doi: 10.1172/jci.insight.94679.

53. Balasubramanian SK, Sadaps M, Thota S, Aly M, Przychodzen BP, Hirsch CM, Visconte V, Radivoyevitch T, Maciejewski JP. Rational management approach to pure red cell aplasia. Haematologica. 2018 Feb;103(2):221-230. doi: 10.3324/haematol.2017.175810. Epub 2017 Dec 7.

54. Balasubramanian SK, Aly M, Nagata Y, Bat T, Przychodzen BP, Hirsch CM, Adema V, Visconte V, Kuzmanovic T, Radivoyevitch T, Nazha A, Mukherjee S, Sekeres MA, Maciejewski JP. Distinct clinical and biological implications of various DNMT3A mutations in myeloid neoplasms. Leukemia. 2018 Feb;32(2):550-553. doi: 10.1038/leu.2017.295. Epub 2017 Sep 22.

55. Kelly KR, Espitia CM, Zhao W, Wu K, Visconte V, Anwer F, Calton CM, Carew JS, Nawrocki ST. Oncolytic reovirus sensitizes multiple myeloma cells to anti-PD-L1 therapy. Leukemia. 2018 Jan;32(1):230-233. doi: 10.1038/leu.2017.272. Epub 2017 Aug 23.

56. Patel BJ, Przychodzen B, Thota S, Visconte V, Clemente MJ, Hirsch CM, Radivoyevitch T, Morawski AC, Souaid R, Nazha A, LaFramboise T, Sakaguchi H, Kojima S, Carraway HE, Sekeres MA, Ogawa S, Makishima H, Maciejewski JP. Genomic Determinants of Chronic Myelomonocytic Leukemia. Leukemia. 2017 Dec;31(12):2815-2823. doi: 10.1038/leu.2017.164. Epub 2017 May 30.

57. Visconte V, Shetty S, Przychodzen B, Hirsch C, Bodo J, Maciejewski JP, Hsi ED, Rogers HJ. Clinicopathologic and molecular characterization of myeloid neoplasms with isolated t(6;9)(p23;q34). Int J Lab Hematol. 2017 Aug;39(4):409-417. doi: 10.1111/ijlh.12641. Epub 2017 Mar 20.

58. Carew JS, Espitia CM, Zhao W, Han Y, Visconte V, Phillips JG, Nawrocki S.Disruption of autophagic degradation with ROC-325 antagonizes renal cell carcinoma pathogenesis. Clin Cancer Res. 2017 Jun 1;23(11):2869-2879. doi: 10.1158/1078-0432.CCR-16-1742. Epub 2016 Nov 23.

59. Visconte V, Przychodzen B, Han Y, Nawrocki ST, Thota S, Kelly KR, Patel BJ, Hirsch C, Advani AS, Carraway HE, Sekeres MS, Maciejewski JP, Carew JS. Complete mutational spectrum of the autophagy interactome: a novel class of tumor suppressor genes in myeloid neoplasms. Leukemia. 2017 Feb;31(2):505-510. doi: 10.1038/leu.2016.295. Epub 2016 Oct 24.

60. Hamilton K, Visconte V, Jia X, Elson P, Tabarroki A, Makishima H, Hasrouni E, Abounader D, Kalaycio M, Sekeres MA, Sobecks R, Duong H, Bolwell B, Maciejewski JP, Copelan E, Tiu RV. Impact of allogeneic hematopoietic cell transplant in patients with myeloid neoplasms carrying spliceosomal mutations. Am J Hematol. 2016 Jun;91(4):406-9. doi: 10.1002/ajh.24306. Epub 2016 Mar 14.

61. Mangaru Z, Shetty S, Visconte V, Liu H, Rogers HJ. Acute myeloid leukemia with inv(16)(p13.1q22), abnormal eosinophils, and absence of peripheral blood and bone marrow blasts. Am J Hematol. 2016. Jun;91(4):E273-4. doi: 10.1002/ajh.24289.

62. Visconte V, Tabarroki A, Hasrouni E, Maciejewski JP, Hsi ED, Tiu RV, Rogers HJ. Molecular and phenotypic heterogeneity of refractory anemia with ring sideroblasts associated with marked thrombocytosis. Leuk Lymphoma. 2016;57(1):212-5. Epub 2015 Jun 25.

63. Visconte V, Nawrocki ST, Espitia CM, Kelly KR, Possemato A, Beausoleil SA, Han Y, Carraway HE, Nazha A, Advani AS, Maciejewski JP, Sekeres MA, Carew JS. Comprehensive quantitative proteomic profiling of the pharmacodynamic changes induced by MLN4924 in acute myeloid leukemia cells establishes rationale for its combination with azacitidine. Leukemia. 2016 May;30(5):1190-4. doi: 10.1038/leu.2015.250. Epub 2015 Sep 15.

64. Ai J, Visconte V, Tabarroki A, Hasrouni E, Hamilton BK, Mukherjee S, Kalaycio M, Sobecks R, Advani AS, Sekeres MA, Shetty S, Tiu RV. Non-translocation (6;9) and non-inversion (3) balanced chromosomal rearrangements are associated with poor survival outcomes in Myelodysplastic syndromes. Clin Lymphoma Myeloma Leuk. 2015 Aug;15(8):489-95. doi: 10.1016/j.clml.2015.03.017. Epub 2015 Apr 2.

65. Shomali W, Redmond C, Bogati S, Zimmerman C, Visconte V, Tabarroki A, Kalaycio M, Tiu RV. Safe and effective use of Ponatinib in a patient with chronic myeloid leukemia and acute venous thromboembolism on therapeutic anti-coagulation. Leuk Lymphoma. 2015 May 5:1-11. Epub ahead of print.

66. Visconte V, Tiu RV, Rogers HJ. Pathogenesis of myelodysplastic syndromes: an overview of molecular and non-molecular aspects of the disease. Blood Res. 2014 Dec; 49(4): 216 - 27.

67. Visconte V, Tabarroki A, Zhang L, Parker Y, Hasrouni E, Mahfouz R, Isono K, Koseki H, Sekeres MA, Saunthararajah Y, Barnard J, Lindner D, Rogers HJ, Tiu RV. Splicing factor 3b subunit 1 (Sf3b1) haploinsufficient mice display features of low risk Myelodysplastic syndromes with ring sideroblasts. J Hematol Oncol. 2014 Dec 7;7(1):89. Epub ahead of print

68. Al-Issa K, Visconte V, Rogers HJ, Dembla V, Lichtin AE, Tiu RV. Cyclosporine dependent Pure Red Cell Aplasia: a Case Presentation. Blood Cells Mol Dis. 2014 Nov 25. pii: S1079-9796(14)00146-6. doi: 10.1016/j.bcmd.2014.11.013. [Epub ahead of print].

69. Chatterjee A, Ghosh J, Ramdas B, Mali RS, Martin H, Kobayashi M, Vemula S, Canela VH, Waskow ER, Visconte V, Tiu RV, Smith CC, Shah N, Bunting KD, Boswell HS, Liu Y, Chan RJ, Kapur R. Regulation of Stat5 by FAK and PAK1 in Oncogenic FLT3- and KIT-Driven Leukemogenesis. Cell Rep. 2014 Nov 20;9(4):1333-48. doi: 10.1016/j.celrep.2014.10.039. Epub 2014 Nov 13.

70. Visconte V, Lindsley RC, Berlyne D. Aplastic Anemia & MDS International Foundation (AA&MDSIF): Bone Marrow Failure Disease Scientific Symposium 2014. Meeting Report. Leuk Res. 2014 Nov 16. pii: S0145-2126(14)00339-7. doi: 10.1016/j.leukres.2014.11.008.

71. Visconte V, Tabarroki A, Gerace CJ, Al-Issa K, Hsi ED, Rogers HJ, Sekeres MA, Silver BJ, Lichtin AE, Mukherjee S, Tiu RV. Screening for SF3B1 mutations is a useful tool to differentiate between acquired clonal from non-clonal sideroblastic anemia. Leuk Lymphoma. 2015 Jun;56(6):1888-90. doi: 10.3109/10428194.2014.976821. Epub 2014 Nov 14.

72. de Melo Campos P, Machado-Neto JA, Scopim-Ribeiro R, Visconte V, Tabarroki A, Duarte ASS, Barra FFC, Vassalo J, Rogers HJ, Lorand-Metze I, Tiu RV, Costa F, Olalla Saad ST, Traina F. Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412. Leuk Res. 2014 Aug 1. pii: S0145-2126(14)00232-X. doi: 10.1016/j.leukres.2014.07.010.

73. Estephan F, Rogers HJ, Visconte V, Tabarroki A, Ai J, Duong HK, Kalaycio ME, Tiu RV. Spontaneous recovery of severe nilotinib-induced bone marrow aplasia and successful re-treatment with dasatinib. Leuk Lymphoma. 2014 Jul 17:1-3

74. Visconte V, Avishai N, Mahfouz R, Tabarroki A, Cowen J, Sharghi-Moshtaghin R, Hitomi M, Rogers HJ, Hasrouni E, Phillips J, Sekeres MK, Heuer AH, Saunthararajah Y, Barnard J, Tiu RV. Distinct iron architecture in SF3B1 mutant Myelodysplastic syndromes patients is linked to an SLC25A37 splice variant with a retained intron. Leukemia. 2014 May 23. doi: 10.1038/leu.2014.170. [Epub ahead of print]

75. Visconte V, Tabarroki A, Zhang L, Hasrouni E, Gerace G, Frum F, Ai J, Advani AS, Duong HK, Kalaycio M, Saunthararajah Y, Sekeres MA, Hsi ED, Shetty S, Rogers HJ, Tiu RV. Clinicopathologic and molecular characterization of myeloid neoplasms harboring isochromosome 17(q10). Am J Hematol. 2014 Aug;89(8):862. doi: 10.1002/ajh.23755. [Epub ahead of print].

76. Visconte V, Selleri C, Maciejewski JP, Tiu RV. Molecular pathogenesis of Myelodysplastic syndromes. Transl Med UniSa. 2014 Feb 4;8:19-30. eCollection 2014 Jan. 77. Tabarroki A, Saunthararajah Y, Visconte V, Cinalli T, Colaluca K, Rogers HJ, Sekeres MA, Duong HK, Stein BL, Tiu RV. Ruxolitinib in combination with DNA methyltransferase inhibitors; clinical responses in symptomatic myelofibrosis patients with cytopenias and elevated blasts counts. Leuk Lymphoma. 2014. May 27:1-3.

78. Tabarroki A, Lindner DJ, Visconte V, Zhang L, Rogers HJ, Parker Y, Duong HK, Lichtin A, Kalaycio M, Sekeres MA, Mountantonakis SE, Heresi GA, Tiu RV. Ruxolitinib leads to improvement of pulmonary hypertension in patients with myelofibrosis. Leukemia. 2014 Jul;28(7):1486-93. doi: 10.1038/leu.2014.5. Epub 2014 Jan 10.

79. Ai J, Visconte V, Rogers HJ, Sekeres MA, Tiu RV. Pure Red Cell Aplasia in a Patient with Cri-Du-Chat. IBRR. 2013. 2(1): 23-28. (article no. IBRR.2014.03)

80. Martin H, Mali RS, Ma P, Chatterjee A, Ramdas B, Sims E, Munugalavadla V, Ghosh J, Mattingly R, Visconte V, Tiu RV, Vlaar C, Dharmawardhane S, Kapur R. Pak and Rac GTPases promote oncogenic KIT-induced neoplasms. J Clin Invest. 2013 Oct 1;123(10):4449-63.

81. Traina F, Visconte V, Elson P, Tabarroki A, Jankowska AM , Hasrouni E, Sugimoto Y, Szpurka H, Makishima H, O'Keefe CL, Sekeres MA, Advani AS, Kalaycio M, Copelan EA, Saunthararajah Y, Olalla Saad ST, Maciejewski JP, and Tiu RV. Impact of Molecular Mutations on Response to DNMT Inhibitors in Myelodysplasia and Related Neoplasms. Leukemia. 2014. Jan;28(1):78-87. doi: 10.1038/leu.2013.269. Epub 2013 Sep 18.

82. Visconte V, Tabarroki A, Rogers HJ, Hasrouni E, Traina F, Makishima H, Hamilton B, Liu Y, O’Keefe C, Lichtin A, Horwitz L, Sekeres MA, Hsieh FH, Tiu RV. SF3B1 mutations are infrequently found in non-MDS bone marrow failure syndromes and mast cell diseases but, if present, are associated with the ring sideroblast phenotype. Haematologica. 2013 Sep;98(9):e105-7. doi: 10.3324/haematol.2013.090506. Epub 2013 Jul 5.

83. Liu Y, Tabarroki A, Billings S, Visconte V, Rogers HJ, Hasrouni E, Englehaupt R, Kalaycio M, Sekeres MA, Saunthararajah Y, Tiu RV. Successful use of very low dose subcutaneous decitabine to treat high-risk myelofibrosis with Sweet’s syndrome that was refractory to 5-azacitidine. Leuk Lymphoma. 2014 Feb;55(2):447-9. doi: 10.3109/10428194.2013.802315. Epub 2013 Jun 24.

84. Tabarroki A, Visconte V, Rogers HJ, Sekeres MA, Samaras C, Lichtin A, Duong H, Englehaupt R, Cinalli T, Dodd K, Desamito J, Rouphail B, Altman J.K, Stein B.L, Tiu RV. Clinical Experiences with Ruxolitinib in Symptomatic MPN Patients with Chronic Kidney Disease. Leuk Lymphoma. 2014 Jan;55(1):213-6. doi: 10.3109/10428194.2013.797086. Epub 2013 Jun 12.

85. Hasrouni E, Rogers HJ, Tabarroki A, Visconte V, Traina T, Afable M, Epstein H, Sekeres MA, Maciejewski JP, Tiu RV. A Case of Mistaken Identity: When Lupus Masquerades as Primary Myelofibrosis. SAGE Open Medical Case Reports. 2013 Jan- Dec 1:2050313X13498709.

86. Mahfouz R, Jankowska AM, Ebrahem Q, Gu Xiaorong, Visconte V, Tabarroki A, Terse P, Covey J, Chan K, Ling Y, Engelke KJ, Sekeres MA, Tiu RV, Maciejewski JP, Radivoyevitch T, Saunthararajah Y. Increased CDA expression/activity in males contributes to worse outcomes with 5-azacytidine or decitabine therapy. Clin Cancer Res. 2013 Feb 15;19(4):938-948.

87. Sekeres MA, Tiu RV, Komrokji R, Lancet J, Advani AS, Afable M, Englehaupt R, Juersivich J, Cuthbertson D, Paleveda J, Tabarroki A, Visconte V, Makishima H, Jerez A, Paquette R, List AF, Maciejewski JP. Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes. Blood. 2012 Dec 13;120(25):4945-51.

88. Traina F, Visconte V, Jankowska AM, Makishima H, O'Keefe CL, Elson P, Han Y, Hsieh FH, Sekeres MA, Mali RS, Kalaycio M, Lichtin AE, Advani AS, Duong HK, Copelan E, Kapur R, Olalla Saad ST, Maciejewski JP, Tiu RV. Single Nucleotide Polymorphism Array Lesions, TET2, DNMT3A, ASXL1 and CBL Mutations Are Present in Systemic Mastocytosis. PLoS ONE. 2012;7(8):e43090. Epub 2012 Aug 15.

89. Visconte V, Rogers HJ, Singh J, Barnard J, Bupathi M, Traina F, McMahon J, Makishima H, Szpurka H, Jankowska A, Jerez A, Sekeres MA, Saunthararajah Y, Advani AS, Copelan E, Koseki H, Isono K, Padgett RA, Osman S, Koide K, O'Keefe C, Maciejewski JP, Tiu RV. SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes. Blood. 2012 Oct 18;120(16):3173-86. Pre-published Jul 23. Plenary Paper.

90. Kar SA, Jankowska AM, Makishima H, Visconte V, Jerez A, Sugimoto Y, Muramatsu H, Traina F, Afable M, Guinta K, Tiu RV, Przychodzen B, Sakaguchi H, Kojima S, Sekeres MA, List AF, McDevitt MA, Maciejewski JP. Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemia. Haematologica. 2012 Jan; 98(1): 107-113.

91. Sakaguchi H, Makishima H, Muramatsu H, Visconte V, Jerez A, Jankowska AM, Tiu RV, Maciejewski JP, Kojima S. Mutational analysis of RNA splicing machinery components in 206 children with myeloid malignancies. Leuk Res. 2012 Dec; 36(12): e215-7.

92. Visconte V, Makishima H, Maciejewski JP, Tiu RV. Emerging roles of the spliceosomal machinery in myelodysplastic syndromes and other hematologic disorders. Leukemia. 2012 Dec;26(12):2447-54.

93. Jerez A, Sugimoto Y, Makishima H, Verma A, Jankowska AM, Przychodzen B, Visconte V, Tiu RV, O'Keefe CL, Mohamedali AM, Kulasekararaj AG, Pellagatti A, McGraw K, Muramatsu H, Moliterno AR, Sekeres MA, McDevitt MA, Kojima S, List A, Boultwood J, Mufti GJ, Maciejewski JP. Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis. Blood. 2012 Jun 21;119(25):6109-17.

94. Sugimoto Y, Sekeres MA, Makishima H, Traina F, Visconte V, Jankowska A, Jerez A, Szpurka H, O'Keefe CL, Guinta K, Afable M, Tiu R, McGraw KL, List AF, Maciejewski J. Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide. J Hematol Oncol. 2012 Mar 5;5:4.

95. Makishima H, Visconte V, Sakaguchi H, Jankowska AM, Abu Kar S, Jerez A, Przychodzen B, Bupathi M, Guinta K, Afable MG, Sekeres MA, Padgett RA, Tiu RV, Maciejewski JP. Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. Blood. 2012 Apr 5;119(14):3203-10.

96. Mali RS, Ramdas B, Ma P, Shi J, Munugalavadla V, Sims E, Wei L, Vemula S, Nabinger SC, Goodwin CB, Chan RJ, Traina F, Visconte V, Tiu RV, Lewis TA, Stern AM, Wen Q, Crispino JD, Boswell HS, Kapur R. Rho kinase regulates the survival and transformation of cells bearing oncogenic forms of KIT, FLT3, and BCR-ABL. Cancer Cell. 2011 Sep 13;20(3):357-69.

97. Visconte V, Makishima H, Jankowska A, Szpurka H, Traina F, Jerez A, O'Keefe C, Rogers HJ, Sekeres MA, Maciejewski JP, Tiu RV. SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts. Leukemia. 2012 Mar;26(3):542-5. doi: 10.1038/leu.2011.232. Epub 2011 Sep 2.

98. Jankowska A, Makishima H, Tiu RV, Szpurka H, Huang Y, Traina F, Visconte V, Sugimoto Y, Prince C, O’Keefe K, Hsi ED, List A, Sekeres MA, Rao A, McDevitt MA, Maciejewski JP. Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation - UTX, EZH2 and DNMT3A. Blood. 2011 Oct 6;118(14):3932-41. Epub 2011 Aug 9.

99. Tiu RV, Visconte V, Traina F, Schwandt A, Maciejewski JP. Updates in Cytogenetics and Molecular Markers in MDS. Curr Hematol Malig Rep. 2011 Jun;6(2):126-35. Review.

100. Sloand EM, Melenhorst JJ, Tucker ZC, Pfannes L, Brenchley JM, Yong A, Visconte V, Wu C, Gostick E, Scheinberg P, Olnes MJ, Douek DC, Price DA, Barrett AJ, Young NS.T cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapy. Blood. 2011. Mar 3;117(9):2691-9. Epub 2010 Nov 19.

101. Montuori N, Bifulco K, Carriero MV, La Penna C, Visconte V, Alfano D, Pesapane A, Rossi FW, Salzano S, Rossi G, Ragno P. The cross-talk between the urokinase receptor and fMLP receptors regulates the activity of the CXCR4 chemokine receptor. Cell Mol Life Sci. 2010. Jul;68(14):2453-67. Epub 2010 Oct 24.

102. de Latour R, Visconte V, Takaku T, Wu C, Erie AJ, Sarcon AK, Desierto MJ, Scheinberg P, Keyvanfar K, Nunez O, Chen J, Young NS. Th17 immune responses contribute to the pathophysiology of aplastic anemia. Blood. 2010. Nov 18;116(20):4175-84. Epub 2010 Aug 23.

103. Visconte V, Raghavachari N, Liu D, Keyvanfar K, Desierto MJ, Chen J, Young NS. Phenotypic and functional characterization of a mouse model of targeted Pig-a deletion in hematopoietic cells. Haematologica. 2010Feb; 95(2):21423.doi:10.3324/haematol.2009.011650. Epub 2009 Aug 13.

104. Sarcon AK, Desierto MJ, Zhou W, Visconte V, Gibellini F, Chen J, Young NS. Role of perforin-mediated cell apoptosis in murine models of infusion-induced bone marrow failure. Exp Hematol. 2009 Apr; 37(4):477-86. Epub 2009 Feb 12.

105. Solomou EE, Wong S, Visconte V, Gibellini F, Young NS. Decreased TCR zeta-chain expression in T cells from patients with acquired aplastic anemia. Br J Haematol. 2007 Jul; 138(1):72-6.

106. Solomou EE, Rezvani K, Mielke S, Malide D, Keyvanfar K, Visconte V, Kajigaya S, Barrett AJ, Young NS. Deficient CD4+CD25+FOXP3+ T regulatory cells in acquired aplastic anemia. Blood. 2007 Sept 1; 110(5):1603-6. Epub 2007 Apr 26.

107. Solomou EE, Gibellini F, Stewart B, Malide D, Berg M, Visconte V, Green S, Childs R, Chanock SJ, Young NS. Perforin gene mutations in patients with acquired aplastic anemia. Blood. 2007 Jun 15; 109(12):5234-7. Epub 2007 Feb 20.

108. Selleri C, Montuori N, Ricci P, Visconte V, Baiano A, Carriero MV, Rotoli B, Rossi G, Ragno P. In vivo activity of the cleaved form of soluble urokinase receptor: a new stem/progenitor cell mobilizer. Cancer Res. 2006 Nov 15; 66(22):10885-90.

109. Selleri C, Ragno P, Ricci P, Visconte V, Scarpato N, Carriero MV, Rotoli B, Rossi G, Montuori N. The metastasis-associated 67-kDa laminin receptor is involved in G-CSF- induced hematopoietic stem cell mobilization. Blood. 2006 Oct 1; 108(7):2476-84. Epub 2006 Jun 20.

110. Montuori N, Visconte V, Rossi G, Ragno P. Soluble and cleaved forms of the urokinase-receptor: degradation products or active molecules? Tromb Haemost. 2005 Feb; 93(2):192-8. Review.

111. de Paulis A, Montuori N, Prevete N, Fiorentino I, Rossi FW, Visconte V, Rossi G, Marone G, Ragno P. Urokinase induces basophil chemotaxis through a urokinase receptor epitope that is an endogenous ligand for formil peptide receptor-like 1 and like 2. J Immunol. 2004 Nov 1; 173(9):5739-48.

112. Selleri C, Montuori N, Ricci P, Visconte V, Carriero MV, Sidenius N, Serio B, Blasi F, Rotoli B, Rossi G, Ragno P. Involvement of the urokinase-type plasminogen activator receptor in hematopoietic stem cell mobilization. Blood. 2005 Mar 1; 105(5):2198-205. Epub 2004 Oct 19. 113. Selleri C, Maciejewski JP, Montuori N, Ricci P, Visconte V, Serio B, Luciano L, Rotoli B. Involvement of nytric oxide in farnesyltransferase inhibitor-mediated apoptosis in chronic myeloid leukemia cells. Blood. 2003 Aug 15; 102(4):1490-8. Epub 2003 Apr 24.

Careers

Training at Lerner Research Institute

Our education and training programs offer hands-on experience at one of the nationʼs top hospitals. Travel, publish in high impact journals and collaborate with investigators to solve real-world biomedical research questions.

Learn More